STOCK TITAN

[8-K] Glucotrack, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Glucotrack, Inc. furnished a press release under Item 7.01 (Regulation FD Disclosure) in a Form 8-K. The company attached the press release as Exhibit 99.1.

The company states the information provided under Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act unless specifically indicated otherwise.

Glucotrack, Inc. ha fornito un comunicato stampa nell’ambito della voce 7.01 (Regulation FD Disclosure) in una Form 8-K. L’azienda ha allegato il comunicato stampa come Exhibit 99.1.

L’azienda afferma che le informazioni fornite nell’ambito della voce 7.01, compreso Exhibit 99.1, sono fornite per informazione e non rientrano nel concetto di “depositato” ai sensi della Exchange Act, salvo diversa indicazione esplicita.

Glucotrack, Inc. presentó un comunicado de prensa bajo el Item 7.01 (Divulgación Regulation FD) en un Formulario 8-K. La empresa adjuntó el comunicado de prensa como Exhibit 99.1.

La empresa afirma que la información proporcionada bajo el Item 7.01, incluido el Exhibit 99.1, se proporciona como información y no se considera “presentada” de acuerdo con la Exchange Act, a menos que se indique lo contrario específicamente.

Glucotrack, Inc. 은 Item 7.01(Regulation FD Disclosure) 아래의 보도자료를 Form 8-K로 제출했습니다. 회사는 보도자료를 Exhibit 99.1로 첨부했습니다.

회사는 Item 7.01 아래 제공된 정보(Exhibit 99.1 포함)가 정보 제공을 위한 것이며 Exchange Act에 따라 “제출된(submitted)” 것으로 간주되지 않는다고 명시합니다, 특별히 달리 표시되어 있지 않는 한.

Glucotrack, Inc. a fourni un communiqué de presse dans le cadre de l’Article 7.01 (Divulgation Regulation FD) dans un Form 8-K. L’entreprise a joint le communiqué de presse en tant que Exhibit 99.1.

L’entreprise déclare que les informations fournies en vertu de l’Article 7.01, y compris Exhibit 99.1, sont fournies à titre informatif et ne sont pas considérées comme déposées au sens de la Exchange Act, sauf indication contraire spécifique.

Glucotrack, Inc. hat eine Pressemitteilung gemäß Item 7.01 (Regulation FD Disclosure) in einem Form 8-K vorgelegt. Das Unternehmen hat die Pressemitteilung als Exhibit 99.1 beigefügt.

Das Unternehmen erklärt, dass die Informationen, die unter Item 7.01, einschließlich Exhibit 99.1, bereitgestellt werden, lediglich zur Information vorliegen und nicht als “eingereicht” im Sinne des Securities Exchange Act gelten, es sei denn, es wird ausdrücklich anders angegeben.

Glucotrack, Inc. قدّمت بياناً صحفياً بموجب البند 7.01 (الإفصاح التنظيمي FD) في نموذج 8-K. أرفقت الشركة البيان الصحفي كـ Exhibit 99.1.

وتذكر الشركة أن المعلومات المقدمة بموجب البند 7.01، بما في ذلك Exhibit 99.1، مقدمة لغرض الإطلاع وليست تعتبر مُودَعة وفقاً لـExchange Act ما لم يذكر خلاف ذلك صراحة.

Positive
  • None.
Negative
  • None.

Glucotrack, Inc. ha fornito un comunicato stampa nell’ambito della voce 7.01 (Regulation FD Disclosure) in una Form 8-K. L’azienda ha allegato il comunicato stampa come Exhibit 99.1.

L’azienda afferma che le informazioni fornite nell’ambito della voce 7.01, compreso Exhibit 99.1, sono fornite per informazione e non rientrano nel concetto di “depositato” ai sensi della Exchange Act, salvo diversa indicazione esplicita.

Glucotrack, Inc. presentó un comunicado de prensa bajo el Item 7.01 (Divulgación Regulation FD) en un Formulario 8-K. La empresa adjuntó el comunicado de prensa como Exhibit 99.1.

La empresa afirma que la información proporcionada bajo el Item 7.01, incluido el Exhibit 99.1, se proporciona como información y no se considera “presentada” de acuerdo con la Exchange Act, a menos que se indique lo contrario específicamente.

Glucotrack, Inc. 은 Item 7.01(Regulation FD Disclosure) 아래의 보도자료를 Form 8-K로 제출했습니다. 회사는 보도자료를 Exhibit 99.1로 첨부했습니다.

회사는 Item 7.01 아래 제공된 정보(Exhibit 99.1 포함)가 정보 제공을 위한 것이며 Exchange Act에 따라 “제출된(submitted)” 것으로 간주되지 않는다고 명시합니다, 특별히 달리 표시되어 있지 않는 한.

Glucotrack, Inc. a fourni un communiqué de presse dans le cadre de l’Article 7.01 (Divulgation Regulation FD) dans un Form 8-K. L’entreprise a joint le communiqué de presse en tant que Exhibit 99.1.

L’entreprise déclare que les informations fournies en vertu de l’Article 7.01, y compris Exhibit 99.1, sont fournies à titre informatif et ne sont pas considérées comme déposées au sens de la Exchange Act, sauf indication contraire spécifique.

Glucotrack, Inc. hat eine Pressemitteilung gemäß Item 7.01 (Regulation FD Disclosure) in einem Form 8-K vorgelegt. Das Unternehmen hat die Pressemitteilung als Exhibit 99.1 beigefügt.

Das Unternehmen erklärt, dass die Informationen, die unter Item 7.01, einschließlich Exhibit 99.1, bereitgestellt werden, lediglich zur Information vorliegen und nicht als “eingereicht” im Sinne des Securities Exchange Act gelten, es sei denn, es wird ausdrücklich anders angegeben.

Glucotrack, Inc. قدّمت بياناً صحفياً بموجب البند 7.01 (الإفصاح التنظيمي FD) في نموذج 8-K. أرفقت الشركة البيان الصحفي كـ Exhibit 99.1.

وتذكر الشركة أن المعلومات المقدمة بموجب البند 7.01، بما في ذلك Exhibit 99.1، مقدمة لغرض الإطلاع وليست تعتبر مُودَعة وفقاً لـExchange Act ما لم يذكر خلاف ذلك صراحة.

Glucotrack, Inc. 已根据第7.01项(Regulation FD披露)在表格8-K中提供了一份新闻稿。公司将新闻稿作为Exhibit 99.1附在文件中。

公司声明,根据信息披露规定第7.01项提供的信息(包括Exhibit 99.1)是提供给参考之用,不被视为依据《证券交易法》而“提交”(filed),除非另有明确说明。

false 0001506983 0001506983 2025-10-28 2025-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 28, 2025

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41141   98-0668934
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

301 Rte. 17 North, Ste. 800, Rutherford, NJ   07070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 842-7715

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GCTK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On October 28, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.

 

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated October 28, 2025
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 28, 2025  
   
  GLUCOTRACK, INC.
     
  By: /s/ Paul Goode
  Name: Paul Goode
  Title: Chief Executive Officer

 

 

Glucotrack

NASDAQ:GCTK

GCTK Rankings

GCTK Latest News

GCTK Latest SEC Filings

GCTK Stock Data

5.87M
799.15k
5.55%
0.81%
4.51%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD